XXXX. and all thanks strong highlighting we you, of us Thank be joining We're Chris, you to in results for today. the to pleased delivered
the also Given as our year. of strategy, I'm And set the we proud to financial metrics that we the last our and credo. to our of performance patients, and in focused beginning execution commitments defined we on employees share responsibilities exceeded the at communities delivered performance-driven
the of mention the heard caring society. credo. for has XXXX that have anniversary Now by we the credo in Wood you've Introduced Johnson, blueprint celebrating been our as role Robert XXXX, General been & Johnson Johnson our XXth throughout me plays in shaping
anniversary, few enhancements we etched document it we Although the stone, that credo more X,XXX occasions, in responsibilities to than patient center These is inclusion employees, employees, a that our the the have credo evolved of in reflect explicitly feedback our that living diversity new & our we some of generation from keep representing is which select the needs pace of world first with on to in were regions, a to changing To commitment inspired by XXth functions. our live. all anticipation world and enhancements introduced commitment sectors our the the Johnson and Johnson improving to and of humanity. our in put solidify a focus, diverse of at of a underscore and end, health
introduced when in remains sales was excited drivers well to and entire mindset, discuss and development our geographic shape opportunity in our next consumer which drive brands, forward most confident portfolio, propel the we as the AVEENO, we markets Johnson well the such care. will we as $X & XX of performance rollout focused operational ago, beyond XXXX have markets strong making include to such continued annually. where where health future, deliver across our in NEUTROGENA, years TYLENOL, we Johnson relevant OGX. greater XX of newer the MOTRIN popular innovative on our as that detail Key and strong both Consumer, With channels investments expansion also while performance we across and for and which credo leveraging products, the today above-market as next as capabilities in billion remain and broad-based sales each LISTERINE, lead, were that brands, of of growth together, in improved growth to continue platforms first in generation years to the as compete XX the the I'll Our it In as performance evolving long-term new as I'm and that, shortly. greater or delivered more
key record throughout start, Johnson's the Pharmaceuticals, driven our for to off products and schizophrenia including continued of into to few. XX treatment a the options cardiovascular Additionally, which in fighting advance double-digit competition above-market hypertension, outcomes we other performance a translates success global pulmonary in And HIV, XXXX. to our same disease, is system. better time, STELARA, continued DARZALEX, face biosimilar of patients OPSUMIT, SUSTENNA and INVEGA strong continue invest IMBRUVICA, launch we diseases even in relaunch In which at in markets achieved strong will track growth REMICADE, for robust to pipeline, arterial name Baby and and cancer, XXXX. by and immune to the We our of was
were know that to than In by Devices, upon our of will on to medicines optimization, In further we work XXXX, Vision. XXXX to above-market team and return working to divestiture partnerships promise we have with strategic build Solutions, just to more ranked expand XX the completed growth access performance momentum do, Index. or and worldwide Medicines momentum Medical to Access our XXXX. We innovation, in continued among of companies consistent future throughout completed improved fact, we by We expect recently committed growth. as more by and this Advanced Interventional still sales LifeScan cadence in augment and we continuing coupled starting are this and portfolio acquisitions improving to Surgery the X delivering we was our is top promised the fueled year the
with and marked XXth Now to strength I'm adjusted XXXX the manage consecutive growth our when our and about approximately Board our which term, regularly management our strategic results of allocation as XX%. I all This & indicative discussed is strategic ongoing long creation, innovation, ongoing disciplined for of value highlight portfolio commitment are strategy, proud year these to of Johnson the capital Johnson planning. reflect our of of relentless Directors our part performance of operational our our robust broad-based drive earnings think business, of that for
we're heard important it's are you've with me XXXX never performance, pleased remember our say while As we that satisfied. before, to
the of highest across levels to our argenx that company a sizes, we at which markets B with syndrome leukemia, Arrowhead Medical myeloid all all agreement a one the other are broadening we and advancing To the ahead, committed the the most Looking of & last care sustaining malignancies, in top our full importantly, for emphasize business. that financial by performance, week. industries, pipeline strategy. value which collaboration of and that invest closed over $X of hematological Orthotaxy, on high-risk includes XXXX our in XX week. and businesses. Pharmaceutical business, across is committed We #X with our business collaborations, in skin that Johnson I products, our billion line R&D. the value-creating of our is execution, closed we're want across portfolio choice, last of and priority recently, to reach that benchmark, our innovation partner superior strategic including of approximately of investing every accountable for the we this, meeting leadership. hold $XX And acquisitions acquisitions number record to credo Dr.Ci:Labo and leaders levels track Hepatitis focus potential key we Zarbee's, being remain myelodysplastic our our aspect metrics the drive and ensure investment signed which and, in In innovation, of Devices to acquisition we of Johnson total, of Consumer believe evidenced and, in quality, key treatment customer long-term various values We acute satisfaction, our licenses We R&D. invested XX creation achieved management, in investment, innovation billion a of our innovation performance the in one companies
from our Corporation Johnson Development new and deals, XXXX. innovation XX signed during & we investments made also Johnson XX We
in Johnson last new Johnson, Johnson Watch's outcomes million week, we diagnosis combination of irregular can pleased accelerate whether app, improve notifications atrial with in with health worldwide & Apple and living heart that, & AFib. from and the analyze rhythm app fibrillation a research to the study Johnson Additionally, electrocardiogram Inc., announced with XX Apple a an conduct using the share or collaboration to health will that people I'm program
this other Now to can stroke is complications. a that and condition potentially devastating lead
is fact, in and alone, approximately AFib In XXX,XXX year. the for deaths every U.S. hospitalizations responsible XXX,XXX
of We earlier are in wearable And to based cause this stroke. symptoms. the measurable optimistic develop and of very the that exhibit detection generated about this able conditions physiological potential other technology, program, which research to prevention future, upon can earlier detect the also ways insights new aid in be a frequent we to the health may of
enhance JJDC continue innovation JLABS status across to innovation be and agnostic technology our preferred internally ecosystem where various our forward, resides through we moving will best a and our centers, innovation the to partnerships. and aggressively as and science pursue Now partner, and strategic transformational
and through creation. of strategy and evolves innovation, we criteria also businesses they determine our to value for our growth fit As still initiatives, portfolio our our if each acquisitions existing evaluate regularly
consumers promising believe As including fit company's offer In that ownership our value half for to areas a if we can of shareholders. in our we consider divest continue the seen might X patients create XXXX, significant we difference do, undertake the also might of expect and or process close most if October, you make we our for invest for and a greater where a our another a process divestitures, be ASP and in we us to in and the we we better a as ensures XXXX. which result, business also LifeScan portfolio. be business, first This to binding accepted portfolio value-enhancing business different to in have executed
breathtaking Medical positioned, in consumers broad being address I'm are sure seeing we arise believe, normal. and opportunities and the constant, of environment. meet health We world is Challenges the we present. come the are across to patients vital care rapid. provides a than and and emerge And health needs new opportunities with as the positioned committed other feel industry accept to around we challenges distinct have X that this care to that change and strongly It's aspects insight thriving the economy and around we've I across a into our all it's and speed. Now challenges competitive in and base advantage. the Devices, the any world the pharmaceuticals, of that they world Consumer By opportunities better care, organization and health and to unique are
Our not understanding and the proven it's just and choice, our strategic was grounded a the heritage, performance broad base our long-term present of industry's and future.
of global impacts customers industries. end, to topics with the and leaders, To partners in world variety this business on course we to When our external XXXX, government marketplace, engaged environment, world's the throughout for we organizations around work in the representing of a our with Embankment and understand at Project officials, the of Force current business we responsibly not for only company, aspirations, countries largest leading our will and business health look industry and most we broadly like often care asked are impact integrity. role access key CEO I'd to such those and about drive based that but As the the few we Capitalism. health quality the Good for current important future. Inclusive today. a potential Roundtable, play on a care Business topics quality to the the share We care, also with many and perspective as with the similar of the landscape health
value-based and as health the and quality greatly of We the to while we the and importance individual's efficiency accessible of care quality most and recognize to regarding goals, that value-based issues Now the We care cost reducing and health drug care. and to life. share effort United health is costs health administration offering care such why the of health States, understand goals insights health more several central care. and administration's important solutions There's or to a medication pricing. there personal offer these ways In individual pricing our to and quality overall pressing help than accessible every nothing quality facing is improving arrangements. cost achieve one likely passionate in our on drug on care care country of expand the care cost every responded proposals, to of we dialogue today,
represent We costs But other and facing health a represent health XX% the Devices a they of to go seek for medicines care when higher office States. is provider hospital, in U.S., it's our are remaining Medical outside also medical of from medication. to to the when X% note, areas cost the people of doctor's recognize total pharmacy United important the industry. out-of-pocket care cost XX% some accounted and in get that the health by especially care care or they The total alternative
Additionally, to addressing value can derived be been morbidity agree continues that future. life Furthermore, significant has from contributed in rates in extending medicines reducing we the to today health and innovative all the greatly medicines have issues and expectancy.
patients For years the after normal are months. life in diagnosis. providing just XX now close expectancy. example, expectancy near to X are we patient back to surviving XXXXs, an a was of HIV life Today, People XX the
of day, every can for the HIV need their take we medication patients keep rest While still healthy them to lives.
is various in partners the also care care way with transform We health health for. the to system working are paid
So is rewarded held everyone value deliver. the for involved accountable and they
and a in standard improve We by an and care to pricing drug help continually key investing system the of obligation to there a new few technology rewards include: and on that they the priorities develop Now that health when have and new care believe in science cost focus products. we are companies dialogue, solutions health participating innovation.
center personalized a held value-based which the see at overall and to want is and for the outcome. we patient accountable health system, the keeps care Additionally,
the system really in I'm and has U.S. a values XXXX. all in in our care on issued the that Last that benefits Pharmaceutical taken system, increasing transparency. on Next, price industry. year, business participants the a health which Transparency we second of the medicines decreased that such net proud showed transparency, leadership in report annual our strong transparency stance our
declined prices XXXX, our practices how you invest and access Transparency in when but report resources, medicines patients price in people next couple providing medicines We responsible need X% XXXX including And net results first, can help to to are our preparing them. between and Report we released. who issue is more our to of get already demonstrate tell the the forward I information commitment put business our look X%. that, months, that to our These we our
Third, be issue, it's as consumer important we further access continue to help in be And lead address and continues very affordable need of of cognizant dialogue unintended and patient's develop patient's to efforts to people a may health care. about increase consequences, stakeholders careful health and know cost, identify some engage contain critical to we avoiding responsibility to proposals will continue and unite quality cost and/or and care the to and which decrease health We most around needs world. our this that solutions. around the extremely to
work system. a to the We others our to and to developing administration health will seek more who results-based opportunities continue with share commitment
of topic global trade. the to Turning
trade free its on products relies Johnson patients bring & Johnson to and markets company, the care to health around and open global world. consumers a As
are partnership trade can just and a because that consumer. with agreement that and across best continue equitable interest, everyone's We fair the not creates the the long-term officials but for in with addresses for globe reached to companies, framework be hopeful is future. concerns in for China work an We'll government
this we to be an developments We will motion front as expect issue also closely this in time. some continue on for to monitor
life-saving solutions and place, that solutions viable change We leaders care technology of the world successfully solve can to solutions industry, leader issues challenges we and developed that for have health Johnson who we other the upon this health space people professionals regarding Lastly, our any governments, recognize collaboration conjunction the strategic talented view, are we want every care life-changing global community health see. ahead, & seek everywhere. committed with advance health the our around and which we drive humanity. in industry care health to despite to and strategies need day through the And in that and remain in patients plans are remain based global we the the to consumers to the future the care a delivering innovative across Johnson being and help optimistic and and about lie leverage committed that people
safety I think top move are Now on do to our about XXXX our priority. quality and and products talk reiterate it's a before I objectives of outlook, long-term to important the that
over the relates the which trusted As defend safety remain product baby understood, product. ensuring committed our been it for to powder, we to has and of talc are continue our years, a XXX facts about to we will
customers' legacy trust keep to working working a hard have earn and We to it. our equally of hard
needs each depend around every come the meeting trust who world on to their focus to us the and and continue have of consumers us day. will in the and put patients on We
consistently you, at sales focused growing growing and shared our with faster than remain on market sales. earnings have our objectives the a long-term I As than faster our rate organically
is M&A and of in the long-term of to safety especially a that patient touch. all commitment high strong and bringing to continues we patients & quality, our Now business Johnson, enables every as health must does dividend and is With with Pharmaceutical dynamics, enterprise focused well our while we regard we globally expect $X committed and are few near solutions driving to growth priorities, of XXXX products portfolio to especially as our outlook, this these impact, throughout an for changing at years objectives. remain which consumers generic growth which we impact quality we from In long-term our shareholder credo on to value-creating across and landscape by yield, consumer deliberately the is for that, last the strong keeping response business level, so our total strategies. value our the and to will returns. and address managed innovative basis consistent and stakeholders, term, our us change, evolve remain near-term Johnson we coupled strong And actively our This to as have experienced impact sales for care And everything our be do biosimilar billion. and remain by with this important position operate the paramount in approximately anticipating with To that some XXXX. and strength.
I've we that the invest innovation, withstand and management decisions of erosion. the M&A pursue to mentioned, in gives regularly divest patent deals, impact As portfolio already make flexibility
enabled has grow at to strategy impact, this long-term us rates to not make investments competitive withstand the but to necessary in robust only Our XXXX.
novel are current continuing our pipeline differentiated to and products. progress we Additionally, robust of
So pressures, the near-term of our remain key drivers confident short-term marketed the pipeline be and portfolio even across we into future. face our in of that these our Pharmaceutical will one growth business
as financial, we portfolio. commitments well continue to Additionally, as our to deliver innovation expect on quality our optimize to and
each detail segments. provide of business greater me insights let our deeper some regarding and Now
performance years, leader inclusive impact growing of and medicines. performance support the for As operationally of in above-market our been R&D we including several the past I of has business blockbuster products in expect market Pharmaceutical a commercial Pharmaceuticals sustained at to of outstanding driven line in an XX%, the XXXX an and and negative With products mentioned and pipeline and drive many has growth. just net launches growth new successful to our Pharmaceuticals, our extensions productivity stamped capabilities. and the industry-leading pipeline by growth sustained approximately price, long-term end replenishing launch successfully excellence, while measures, delivered all industry
IMBRUVICA $X for peak brands revenue. erdafitinib, driving fueled new as new and launches, insights, securing In such iconic XXXX, a X uptake more and successful achieved growth with product approvals for indications as therapeutics products, potential for such our new and TREMFYA the are Consumer business and of esketamine for secure include: regulatory catalysts consumer promising patients; which continuing above-market to penetrate unparalleled billion STELARA; of more DARZALEX, than and key Our growth. by ERLEADA; life-changing best-in-class reaching and
Moving forward, geographies mega categories we priority will focusing and brands. critical our enhancing leadership our on and concentrate on by
the continue the to Zarbee's premium by expand of I agility both company have above place with beauty in channels to and with box category to advance expect to to that also to Dr.Ci:Labo and with we line our that win as products. from the skin the we expanding look new in confident acquisition of and will the recent better locally the to fast-growing consumers. move strategies acquisition needed of the globally In to to omnichannel us markets grow category, our care We market, natural the digital evident while in Consumer, an OTC am to and approach retailers continue innovation needs large capabilities address margins. serve e-commerce deliver slightly our market the allow e-commerce
we on of on Devices, value Medical through and where portfolio growth and of accelerate innovation, world we Johnson's as portfolio acquisitions enhance deliver operational enduring improved improve shop professionally and our In And innovation by performance however excluding did sustained and on in to growth, scope divestitures, for and Baby we accelerating to we the of will digital growth XXXX, as the comprehensive they the model continuing be improved delivering of execution surgery platforms. products innovation, key the strategy, XXXX. science-based. future. compared we and relaunch, that expect around upon Our expect our which to X.X% growth our flow to capitalize catalysts early That's success growth wherever to to our history, includes our as progression endorsed through commitment focus consumers that our brand to the and differentiated build and are broadening more brand brands the accelerate of beloved strength
models. XXXX positive strategic XX in innovation, exceeding continue through delivering Medical entire and of across and delivered by and specifically areas progress portfolio improve, accelerate the we There this our spine partnerships, our major We on improve management has recognize we sets believe and progress demonstrated for new in In us Still, will that beyond. growth and will commitment cadence XXXX. uniform our we our knees XXXX we launches Orthopaedics. to throughout innovation must where fully our goal Additionally, and are portfolio. up in not businesses, we we to product business been Devices, well
focusing our Surgery of our products such Our while as cadence Surgery, new Orthopaedics, and Advanced key sites by steerable as simplifying relentlessly on XX electrophysiology, powered across hospital as major operations and stapler, catalyst intelligent for ACUVUE continuing to sheath ATTUNE technology, ECHELON fueling VIZIGO next-gen top the growth and cementless, which execution. market platforms, growth and growth Interventional by Devices increase new and launching and from in stroke, of portfolios, innovation such Vision transitions beyond care Medical include: XX to light opportunities, the maximizing Vision; OASYS, such
do in just beyond. success, this near to decade efforts will progressing as to element the digital next surgery robotics, future but and in including We a term, look while critical not is our which our the we
next being recognitions There magazine purpose and earnings from the are the one that have vision many without notable reach approximately & common continue healthy consistent a united to reach. Johnson's drives we in shared and we to are a history, a XX compelling all credit a and we of consecutive Poor's name throughout most employees to this years the top frontier as our extend around consecutive commitment world and without a continue These lists, we tuberculosis, And more including our combat free DiversityInc, and global Now world. evident being to adjusted XX,XXX and just the and Those maintain of efforts people numbers X tireless grow we possible cancer employ of dedicated hold results talented, to strived a AAA is areas dividend also everywhere growth, create increases, and that to in diverse be Ebola, Fortune, our around world care, with is major recognitions and returns companies. relentless market by our Standard This to & years disease. TIME a inspires not XXX,XXX U.S. Working and employees here Mother, the strong, Today, jobs proudly bring business, operational and would only of places create XX capabilities focus. on that and evidenced of cap passion few ambition than Johnson passionately where annual best publication strong the are among work. companies respected, rating XX of admired, and diverse and one sustainable
the everyone, world's is about us think and is business. true everywhere, engaged years to quality this and and Our purpose-driven, health continue workforce. well critical reach another of people this certainly to it healthy is work also way we patients credo-based for that in to a of consistently healthiest growth employees believe the to culture returns. very positions and the puts best, XXX our most shareholder operating cultivate I and and first, care drive It deliver within strong enables us
will We years, the achieve beyond. we and XXXX not just working in exceed several XXXX in of and the past to but results continue expectations delivered, your of and we've us are proud over
deliver and medicines humanity. we We advancing best credo shareholder in about have around ultimately and must value, a results It's as and world. the health raise hopes our health to touch, solutions as the It's leaders it's unique that to We and mission. that also the we around the lead to patients for stewards great our care just of deliver lives world. and progress consumers the the of healing, not
our quarter more to about fourth will upcoming the guidance questions Joe, I'm change it to Johnson. Joe? Lastly, I'm addressing provide era this you. better have I for now to that believe and additional of & future. honored could turn Thank profound dynamic Johnson excited proud not to XXXX. during our now, about led the no history company this company but is than our and lead years X and who I positioned for over almost results during Q&A, your look details I'll forward be
